IMDX

Insight Molecular Diagnostics In…

• TipRanks·05/20 05:35

  Insight Molecular Diagnostics Balances Progress and Cash Burn

• TipRanks·05/15 12:01

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (AQST), Sangamo Therapeutics (OtherSGMO) and Insight Molecular Diagnostics (IMDX)

• TipRanks·05/15 00:31

  OncoCyte’s Earnings Call Maps Risky Path to Launch

• TipRanks·05/14 13:19

  Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)

• TipRanks·05/14 11:45

  Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed

• Benzinga·05/14 09:03

  Insight Molecular Q1 2026 Earnings Call Transcript

• Seeking Alpha·05/14 00:31

  Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M

• Reuters·05/13 20:22

  Insight Molecular Diagnostics Q1 loss narrows as costs drop

• Dow Jones·05/13 20:17

  *Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX

• Dow Jones·05/13 20:17

  *Insight Molecular Diagn 1Q Rev $32,000 >IMDX

• PUBT·05/13 20:14

  Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000

• Seeking Alpha·05/13 20:12

  Insight Molecular Diagnostics Inc. GAAP EPS of -$0.12 beats by $0.14, revenue of $0.32M beats by $0.09M

• PUBT·05/13 20:06

  Insight Molecular Diagnostics amends 8-K, reclassifies Quest agreement disclosure to Item 8.01

• Benzinga·05/13 20:06

  Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate

• Dow Jones·05/13 20:05

  Press Release: IMDX Reports Q1 2026 Results and -4-